111 Inc YI reported a Q2 FY23 net revenue increase of 14.5% Y/Y to RMB3.5 billion ($479.6 million).
B2B revenues grew 15.5% Y/Y to RMB3.4 billion, while B2C revenue declined 13.4% Y/Y to RMB88.8 million.
The company's gross segment profit rose 8.3% Y/Y in the quarter on 11.6% Y/Y growth in the B2B segment profit.
Adjusted operating loss stood at RMB(17.2) million ($2.4 million), vs. adjusted loss from operations of RMB(52.8) million a year ago.
The company reported an adjusted loss per ADS of RMB(0.38), equivalent to $(0.06), better than the adjusted loss per share of RMB(0.82) the prior year.
As of June 30, 2023, cash and cash equivalents, restricted cash, and short-term investments stood at RMB735.8 million ($101.5 million).
As of Q2, YI had relationships with over 500 pharmaceutical partners and optimized operations for around 435,000 retail pharmacies.
"Our recent achievements are a direct result of our unwavering strategic focus, particularly on digitization. In June, we forged a strategic alliance with Tencent to amplify the reach of online pharmaceutical services. By July, 111 secured a spot on the Shanghai Data Exchange, propelling the digital transformation of the pharmaceutical landscape. That same month, we unveiled a pivotal digital supply chain product, bolstering the momentum of supply-side digitization. This quarter, in acknowledgment of 111's digital prowess, the Ministry of Commerce distinguished us as an E-commerce Demonstration Enterprise, placing us among the top 132 nationwide," said Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer.
Price Action: YI shares closed at $2.95 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.